| First Author | Corthay A | Year | 2005 |
| Journal | Immunity | Volume | 22 |
| Issue | 3 | Pages | 371-83 |
| PubMed ID | 15780993 | Mgi Jnum | J:97169 |
| Mgi Id | MGI:3574696 | Doi | 10.1016/j.immuni.2005.02.003 |
| Citation | Corthay A, et al. (2005) Primary antitumor immune response mediated by CD4+ T cells. Immunity 22(3):371-83 |
| abstractText | Gene-targeted mice have recently revealed a role for lymphocytes and interferon-gamma (IFNgamma) in conferring protection against cancer, but the mechanisms remain unclear. Here, we have characterized a successful primary antitumor immune response initiated by naive CD4+ T cells. Major histocompatibility complex class II (MHC-II)-negative myeloma cells injected subcutaneously into syngeneic mice were surrounded within 3 days by macrophages that captured tumor antigens. Within 6 days, naive myeloma-specific CD4+ T cells became activated in draining lymph nodes and subsequently migrated to the incipient tumor site. Upon recognition of tumor-derived antigenic peptides presented on MHC-II by macrophages, the myeloma-specific CD4+ T cells were reactivated and started to secrete cytokines. T cell-derived IFNgamma activated macrophages in close proximity to the tumor cells. Tumor cell growth was completely inhibited by such locally activated macrophages. These data indicate a mechanism for immunosurveillance of MHC-II-negative cancer cells by tumor-specific CD4+ T cells through collaboration with macrophages. |
